Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
BA

BAYRYStock

Healthcare

$15.70 last close 2026-11-16
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment BAYRY's does — no target price to set, unlike a price alert.

Sharia status
NOT COMPLIANT
Per our in-house ratio engine
0 of 7 pass our own screen — all 7 agree here
Purification 100.00% *HTR non-permissible income 1.03%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure2 of 5 timeframes bullish · 69.6% aligned
VWAPPrice holding above VWAP ($15.69)
VolumeRelative volume 1.4× the 20-day average
Momentum10-day rate of change +12.5%

BAYRY is currently considered not halal (non-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

438 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →

Market & analysts
Price target
$16.07
+2.4% · 4 analysts
Institutional own.
0.3%
of shares
Momentum (10d)
+12.5%
rate of change
SMC grade
C · 55
69.6% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
1.03%
Non-permissible income — HTR, from filings (2025-12-31)
C · 55
SMC grade — 69.6% timeframe alignment
+12.5%
Rate of change (10d)
$16.07
Price target (+2.4%) · 4 analysts
0.3%
Institutional ownership

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2025-12-31. These ratios come from the issuer's own published statements rather than structured SEC data.

Business activity: cleared (no excluded categories detected)

AAOIFI Fail 2 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 75.73% 30.00% Fail
Interest-bearing investments 16.32% 30.00% Pass
Non-permissible income 1.03% 5.00% Pass
Usmani Fail 3 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 36.10% 33.00% Fail
Interest-bearing investments 7.51% 33.00% Pass
Non-liquid assets 83.80% at least 20.00% Pass
Non-permissible income 1.03% 5.00% Pass
MSCI Fail 3 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 34.87% 33.33% Fail
Cash + interest-bearing securities 7.51% 33.33% Pass
Accounts receivable 16.20% 33.33% Pass
Non-permissible income 1.03% 5.00% Pass
FTSE Fail 3 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 34.87% 33.33% Fail
Cash + interest-bearing securities 7.51% 33.33% Pass
Accounts receivable 16.20% 50.00% Pass
Non-permissible income 1.03% 5.00% Pass
Dow Jones Islamic Market Fail 3 of 4 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 125.09% 33.00% Fail
Cash + interest-bearing securities 26.96% 33.00% Pass
Accounts receivable 31.15% 33.00% Pass
Non-permissible income 1.03% 5.00% Pass
S&P Shariah Fail 3 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 133.32% 33.00% Fail
Cash + interest-bearing securities 28.73% 49.00% Pass
Accounts receivable 33.20% 49.00% Pass
Non-permissible income 1.03% 5.00% Pass
MSCI M-Series Fail 2 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 133.32% 33.33% Fail
Cash + interest-bearing securities 28.73% 33.33% Pass
Accounts receivable 61.93% 49.00% Fail
Non-permissible income 1.03% 5.00% Pass

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

Dow Jones Islamic Market (% of 24-mo avg market cap)receivables ratio 1.9pts
AAOIFI Standard 21 (% of market cap)non permissible income ratio 4.0pts
Usmani (% of total assets)non permissible income ratio 4.0pts
S&P Shariah Indices (% of 36-mo avg market cap)debt ratio 100.3pts
MSCI Islamic M-Series (% of 36-mo avg market cap)debt ratio 100.0pts
Dow Jones Islamic Market (% of 24-mo avg market cap)debt ratio 92.1pts

The numbers the ratios are built from

Read from BAYRY's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $53.6B 2025-12-31 yahoo:annualTotalRevenue
Interest-bearing debtShort and long-term borrowings $42.8B 2025-12-31 yahoo:annualTotalDebt
Cash and interest-bearing securitiesCash, equivalents and marketable securities $9.2B 2025-12-31 yahoo:annualCashCashEquivalentsAndShortTermInvestments
Total assetsBalance sheet total $122.8B 2025-12-31 yahoo:annualTotalAssets
Market capDenominator for AAOIFI $56.6B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $8.6B 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $8.7B 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $553.4M 2025-12-31 yahoo:annualInterestIncome

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

What changed, and when

Verdict history for BAYRY. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for BAYRY has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

Tracked investors holding BAYRY
InvestorFirmPositionWeightAs of
Kahn Brothers Kahn Brothers Group $89M 14.1% 2026-06-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

15.9813.9011.829.747.662025-11-172026-05-192026-11-16

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
15.48
S2
15.54
S1
15.60
PIVOT
15.66
R1
15.72
R2
15.78
R3
15.84

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
13.68 – 14.94
±4.4% from 14.31, made 2026-09-10 · resolves 2026-09-17
STRONG BUY
from 19 indicators
74.9% of our last 10571 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 50.2% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG BUY
19 indicators
OscillatorsNEUTRAL
3 buy · 1 neutral · 3 sell
Moving averagesSTRONG BUY
12 buy · 0 neutral · 0 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)72.40SELL
Stochastic %K (14)91.32SELL
CCI (20)76.40NEUTRAL
Williams %R (14)-8.68SELL
MACD (12,26,9)0.17BUY
ROC (10)12.47BUY
Momentum (10)1.74BUY
EMA (10)15.32BUY
SMA (10)15.53BUY
EMA (20)14.64BUY
SMA (20)14.22BUY
EMA (30)14.28BUY
SMA (30)13.58BUY
EMA (50)13.95BUY
SMA (50)13.69BUY
EMA (100)13.49BUY
SMA (100)13.83BUY
EMA (200)12.63BUY
SMA (200)12.65BUY

About BAYRY

Healthcare · Drug Manufacturers - General

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. It has a commercial agreement with Neste to Jointly scale newgold winter canola for biofuels production. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

bayer.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Average — needs more confirmation before sizing up

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BULLISH 43
⏰ 4H BULLISH 35
🕐 1H RANGING 98
⏱ 15-Min BEARISH 130
⏲ 5-Min RANGING 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

+12.5%
Rate of change (10d)
1.4×
Volume vs its 20-day average
0.72
MACD (no fresh cross)
$15.74
Volume POC (today)
$15.73 – $15.77
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-03 · Asset managers net 928584 (+5135)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.